<DOC>
	<DOCNO>NCT01140893</DOCNO>
	<brief_summary>The purpose study determine whether exenatide effective improve glycemic control among type 2 diabetic patient treat insulin pump therapy .</brief_summary>
	<brief_title>Effects Exenatide Glycemic Control Weight Continuous Subcutaneous Insulin Infusion ( CSII ) Type 2 Treated Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Men woman age 35 70 Type 2 diabetes diagnose least 12 month , accord criterion American Diabetes Association : presence classic symptom diabetes mellitus unequivocal elevation plasma glucose ( 2hour postprandial random glucose &gt; 200 mg/dL ) fast plasma glucose elevation 1 occasion &gt; 125 mg/dL patient currently undergo pharmacological and/or nonpharmacological treatment diabetes mellitus CSII treatment use rapid analog least 6 month ( CSII initiate patient HbA1c &gt; 8 % despite wellconducted MDI trial use 2 5 daily injection regimen ) HbA1c ≥ 7,5 % ≤ 10 % BMI ≥ 25 ≤ 45 Stable body weight ( ≤10 % variation ) 3 last month Type 1 diabetes assess positive antiGAD65 antiinsulin antiIA2 antibodies Monogenic diabetes ( MODY , mitochondrial diabetes… ) Current treatment OHA ( OHA ought interrupt least two month prior inclusion study ) Current treatment specifically address weight lost ( orlistat , sibutramine , rimonabant may interrupt least 3 month prior inclusion study ) Use corticosteroid therapy 10 day within 3past month , patient ought treat corticosteroid study period Clinically significant hepatic disease Documented gastroparesis , current use drug directly affect gastrointestinal motility , significant abdominal disease may increase risk adverse gastrointestinal effect induce exenatide Kidney failure ( MDRD le 50 ml/min ) Pregnancy/breastfeeding Any social and/or mental condition render subject unable understand scope possible consequence study Concurrent enrolment another clinical trial Geographically inaccessible followup visit require protocol</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>CSII</keyword>
	<keyword>Exenatide</keyword>
	<keyword>Double Blind Placebo Controlled Study</keyword>
</DOC>